Growing data collection concerns in a pandemic environment
Market research: decentralized clinical trials
COVID-19 has forced the clinical research community to re-evaluate data collection methods in a pandemic.
How has the pandemic changed clinical trial management?
New research indicates an accelerated adoption of decentralized clinical trial models.
COVID-19 has forced life sciences organizations to quickly accelerate their adoption of decentralized clinical trial methods, introducing new technologies for patient data collection and thereby increasing the volume and variety of data, raising valid concerns about data quality and regulatory compliance. A recent global, industry-wide survey conducted by Informa Pharma Intelligence explored the impact of the pandemic on clinical operations and provides valuable insight into how your peers are managing patient data collection in this new paradigm and gives perspective on what lies ahead as this shift to decentralized trials continues.
The fundamental shifts in clinical trial complexity demand better operational methods.
To see how clinical trial management is evolving to tackle the new challenges faced by sponsors and clinical research organizations, visit our microsite "The Future of Clinical Trials" for more information on the changing data landscape, decentralized clinical trials and the environment needed to support them.
If you no longer wish to receive communications from Oracle, please opt out here.
Want to reach 137,000+ Fierce Biotech subscribers with your own message? Contact aalcover@questex.com or call 202-824-5074.
You are currently subscribed as newsletter@newslettercollector.com. If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe. Refer to our Privacy Policy.
Questex, LLC 685 3rd Avenue, 21st Floor New York, NY 10017
